264 related articles for article (PubMed ID: 19167366)
1. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
Kirkland LO; McInnes C
Biochem Pharmacol; 2009 May; 77(10):1561-71. PubMed ID: 19167366
[TBL] [Abstract][Full Text] [Related]
2. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
3. Protein kinases: From targets to anti-cancer drugs.
Cruzalegui F
Ann Pharm Fr; 2010 Jul; 68(4):254-9. PubMed ID: 20637357
[TBL] [Abstract][Full Text] [Related]
4. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
5. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
6. Promises and drawbacks of targeting cell cycle kinases in cancer.
Pentimalli F; Giordano A
Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
8. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.
Duncan JS; Haystead TA; Litchfield DW
Methods Mol Biol; 2012; 795():119-34. PubMed ID: 21960219
[TBL] [Abstract][Full Text] [Related]
9. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
10. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
11. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
12. [Progress in the design of selective ATP-competitive kinase inhibitors].
Deng XQ; Xiang ML; Jia R; Yang SY
Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
[TBL] [Abstract][Full Text] [Related]
13. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
14. Targeting protein kinases in cancer therapy: a success?
Pearson MA; Fabbro D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1113-24. PubMed ID: 15606337
[TBL] [Abstract][Full Text] [Related]
15. AKT crystal structure and AKT-specific inhibitors.
Kumar CC; Madison V
Oncogene; 2005 Nov; 24(50):7493-501. PubMed ID: 16288296
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
18. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
20. Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
Fasano M; Della Corte CM; Califano R; Capuano A; Troiani T; Martinelli E; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2014 Jun; 23(6):809-21. PubMed ID: 24673358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
